The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer
Clinicaltrials.gov identifier:
NCT02975934
Treatment
Study Contact Information:
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
The study is open and recruiting at sites in CA, FL, GA, HI, MD, NE, NV, NJ, NY, NC, OH, TN, TX, VA.
A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
About the Study
The purpose of Triton3 is to determine how patients with castration-resistant cancer, and an inherited gene mutation or tumor genetic deficiency respond to treatment with the rucaparib () compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients.
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
NOTE: This study is no longer enrolling patients.
NOTE: This study is no longer enrolling patients.